Bellerophon Therapeutics, Inc.

OTCPK:BLPH 주식 보고서

시가총액: US$685.0k

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Bellerophon Therapeutics 관리

관리 기준 확인 0/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Craig Jalbert

최고 경영자

n/a

총 보상

CEO 급여 비율n/a
CEO 임기less than a year
CEO 소유권n/a
경영진 평균 재임 기간데이터 없음
이사회 평균 재임 기간데이터 없음

최근 관리 업데이트

Recent updates

Bellerophon Therapeutics (NASDAQ:BLPH) Will Have To Spend Its Cash Wisely

Jan 06
Bellerophon Therapeutics (NASDAQ:BLPH) Will Have To Spend Its Cash Wisely

Bellerophon stock gains ~24% after getting FDA nod to reduce phase 3 study size

Sep 27

Bellerophon Therapeutics GAAP EPS of -$0.43 beats by $0.17

Aug 15

Is Bellerophon Therapeutics (NASDAQ:BLPH) In A Good Position To Invest In Growth?

Jan 18
Is Bellerophon Therapeutics (NASDAQ:BLPH) In A Good Position To Invest In Growth?

Bellerophon Therapeutics EPS misses by $0.01

Nov 05

CEO

Craig Jalbert (62 yo)

less than a year

테뉴어

Mr. Craig R. Jalbert, CIRA, serves as President, CEO, Treasurer, Secretary and Director of eFFECTOR Therapeutics, Inc. since June 2024. He serves as President, Corporate Secretary, Principal Executive Offi...